Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 24,153,462
  • Shares Outstanding, K 607,176
  • Annual Sales, $ 2,289 M
  • Annual Income, $ 619,730 K
  • 60-Month Beta 0.36
  • Price/Sales 10.75
  • Price/Cash Flow 13.59
  • Price/Book 2.43
Trade RPRX with:

Options Overview Details

View History
  • Implied Volatility 55.03% ( -0.47%)
  • Historical Volatility 34.87%
  • IV Percentile 97%
  • IV Rank 81.54%
  • IV High 62.48% on 08/10/21
  • IV Low 22.11% on 12/22/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 90
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 19,705
  • Open Int (30-Day) 19,260

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate 0.77
  • Number of Estimates 4
  • High Estimate 0.82
  • Low Estimate 0.70
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +8.45%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.07 +6.61%
on 05/10/22
44.22 -10.64%
on 04/21/22
-4.70 (-10.63%)
since 04/20/22
3-Month
36.15 +9.32%
on 02/24/22
44.75 -11.69%
on 04/14/22
+0.11 (+0.28%)
since 02/18/22
52-Week
34.86 +13.37%
on 10/06/21
47.10 -16.09%
on 06/07/21
-1.08 (-2.66%)
since 05/20/21

Most Recent Stories

More News
Here's Every Stock Warren Buffett Bought or Sold in the First Quarter

The Oracle of Omaha was very active in the markets.

ORCL : 68.63 (+2.37%)
BRK.A : 456,500.00 (+0.10%)
BRK.B : 304.05 (-0.03%)
BRK-A : N/A (unch)
BRK-B : N/A (unch)
OXY : 63.26 (-1.09%)
HPQ : 34.65 (-3.02%)
C : 49.75 (-0.06%)
PARA : 32.64 (+1.30%)
CE : 150.73 (+0.47%)
MCK : 322.86 (+1.17%)
MKL : 1,333.08 (-1.61%)
Royalty Pharma plc (RPRX) Q1 2022 Earnings Call Transcript

RPRX earnings call for the period ending March 31, 2022.

RPRX : 39.52 (-0.65%)
Royalty Pharma (RPRX) Lags Q1 Earnings Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of -15.28% and 3.64%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

RPRX : 39.52 (-0.65%)
ATLC : 35.16 (+1.50%)
Royalty Pharma Reports First Quarter 2022 Results

Net cash provided by operating activities (GAAP) of $460 million; Adjusted Cash Receipts(1) (non-GAAP) of $605 million Announced transactions of up to $450...

RPRX : 39.52 (-0.65%)
Royalty Pharma Declares Second Quarter 2022 Dividend

NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) --  The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...

RPRX : 39.52 (-0.65%)
Royalty Pharma to Announce First Quarter 2022 Financial Results on May 5, 2022

NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2022 financial...

RPRX : 39.52 (-0.65%)
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

RPRX : 39.52 (-0.65%)
Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at...

RPRX : 39.52 (-0.65%)
Royalty Pharma Announces Inaugural Investor Day

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an inaugural Investor Day in New York...

RPRX : 39.52 (-0.65%)
Royalty Pharma plc (RPRX) Q4 2021 Earnings Call Transcript

RPRX earnings call for the period ending December 31, 2021.

RPRX : 39.52 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 42.07
2nd Resistance Point 41.27
1st Resistance Point 40.40
Last Price 39.52
1st Support Level 38.73
2nd Support Level 37.93
3rd Support Level 37.06

See More

52-Week High 47.10
Fibonacci 61.8% 42.42
Fibonacci 50% 40.98
Fibonacci 38.2% 39.54
Last Price 39.52
52-Week Low 34.86

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar